BR112023027025A2 - Métodos de uso de inibidores da aldosterona sintase - Google Patents
Métodos de uso de inibidores da aldosterona sintaseInfo
- Publication number
- BR112023027025A2 BR112023027025A2 BR112023027025A BR112023027025A BR112023027025A2 BR 112023027025 A2 BR112023027025 A2 BR 112023027025A2 BR 112023027025 A BR112023027025 A BR 112023027025A BR 112023027025 A BR112023027025 A BR 112023027025A BR 112023027025 A2 BR112023027025 A2 BR 112023027025A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- aldosterone synthase
- synthase inhibitors
- subject
- compound
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 208000016998 Conn syndrome Diseases 0.000 abstract 1
- 101000761956 Homo sapiens Cytochrome P450 11B2, mitochondrial Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000013846 primary aldosteronism Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214521P | 2021-06-24 | 2021-06-24 | |
| US202163290364P | 2021-12-16 | 2021-12-16 | |
| PCT/US2022/073148 WO2022272300A1 (en) | 2021-06-24 | 2022-06-24 | Methods of using aldosterone synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023027025A2 true BR112023027025A2 (pt) | 2024-03-12 |
Family
ID=84545863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023027025A BR112023027025A2 (pt) | 2021-06-24 | 2022-06-24 | Métodos de uso de inibidores da aldosterona sintase |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277698A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4358959A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523559A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240035483A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022299103B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023027025A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3223211A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309428A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023015121A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022272300A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026521801A (ja) * | 2023-06-29 | 2026-07-01 | アストラゼネカ アイルランド リミテッド | バクスドロスタットの結晶形、並びにその製造方法及びその使用 |
| CN121712504A (zh) * | 2023-07-27 | 2026-03-20 | 矿物疗法公司 | 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法 |
| IL329013A (en) * | 2023-12-15 | 2026-08-01 | Astrazeneca Ireland Ltd | SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension |
| WO2026120166A1 (en) | 2024-12-06 | 2026-06-11 | AstraZeneca Ireland Limited | Tablet formulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996024358A1 (en) * | 1995-02-10 | 1996-08-15 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
| AU4866196A (en) * | 1995-02-10 | 1996-08-27 | G.D. Searle & Co. | Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic |
| US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| CA2832996C (en) * | 2011-04-26 | 2019-05-07 | Merck Sharp & Dohme Corp. | Tricyclic triazole compounds and their use as aldosterone synthase inhibitors |
| US9353081B2 (en) * | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
-
2022
- 2022-06-24 JP JP2023579554A patent/JP2024523559A/ja active Pending
- 2022-06-24 WO PCT/US2022/073148 patent/WO2022272300A1/en not_active Ceased
- 2022-06-24 EP EP22829524.2A patent/EP4358959A4/en active Pending
- 2022-06-24 KR KR1020247002601A patent/KR20240035483A/ko active Pending
- 2022-06-24 US US18/569,853 patent/US20240277698A1/en active Pending
- 2022-06-24 BR BR112023027025A patent/BR112023027025A2/pt unknown
- 2022-06-24 AU AU2022299103A patent/AU2022299103B2/en active Active
- 2022-06-24 MX MX2023015121A patent/MX2023015121A/es unknown
- 2022-06-24 CA CA3223211A patent/CA3223211A1/en active Pending
- 2022-06-24 IL IL309428A patent/IL309428A/en unknown
-
2026
- 2026-03-16 AU AU2026201954A patent/AU2026201954A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4358959A1 (en) | 2024-05-01 |
| CA3223211A1 (en) | 2022-12-29 |
| WO2022272300A1 (en) | 2022-12-29 |
| MX2023015121A (es) | 2024-04-16 |
| IL309428A (en) | 2024-02-01 |
| KR20240035483A (ko) | 2024-03-15 |
| US20240277698A1 (en) | 2024-08-22 |
| JP2024523559A (ja) | 2024-06-28 |
| AU2026201954A1 (en) | 2026-04-02 |
| AU2022299103A1 (en) | 2024-01-25 |
| EP4358959A4 (en) | 2025-05-14 |
| AU2022299103B2 (en) | 2025-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| MX2023015121A (es) | Metodos de uso de inhibidores de aldosterona sintasa. | |
| BR112023014751A2 (pt) | Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão | |
| BR112012010705A2 (pt) | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
| BR112023023527A2 (pt) | Inibidores de nlrp3 | |
| BR112022000713A2 (pt) | Imidazopirimidinas como inibidores de eed e o uso das mesmas | |
| BRPI0611923A2 (pt) | modulaÇço sinergica da ftl3 quinase usando os moduladores de quinase aminoquinolina e aminoquinazolina | |
| BR112022001341A2 (pt) | Inibidores de enzima | |
| BR112012004453A8 (pt) | composto inibidor de proteína quinase, sua composição farmacêutica e seu uso | |
| BR112013021638A2 (pt) | "compostos inibidores de trk, seu uso e composições que os compreendem" | |
| BR112012021659A2 (pt) | composto, composição farmacêutica, método para tratar e/ou prevenir distúrbios e doenças. | |
| BR112021020520A2 (pt) | Inibidores da di-hidro-orotato desidrogenase | |
| ECSP22026478A (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| BR112018072339A2 (pt) | tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados | |
| BR112022001390A2 (pt) | Inibidores de enzima | |
| BR112022001054A2 (pt) | Inibidores enzimáticos | |
| BR112023025916A2 (pt) | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção | |
| BR112023026538A2 (pt) | Pirazóis com pirimidinil substituído como inibidores de cdk2 | |
| BR112022022305A2 (pt) | Combinação farmacêutica que compreende tno155 e nazartinibe | |
| EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами |